ACXP - Acurx Pharmaceuticals LLC logo

Acurx Pharmaceuticals LLC

ACXP

Acurx Pharmaceuticals develops novel antibiotics targeting difficult bacterial infections. Its lead candidate, ibezapolstat, is in Phase 2b trials for Clostridium difficile, while ACX-375C aims to combat drug-resistant gram-positive bacteria.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$12today

Score Overview

1 Year
Scoreโ€”
Net Growth5.78%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth40.81%
Net Trend80%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth40.81%
Net Trend80%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Acurx Pharmaceuticals LLC has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ACXP does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 1.14โ€”
1 Year2025-10-23
$ 6.50-82.54%
5 Years2021-10-22
$ 96.40-98.82%
All Time2021-06-25
$ 157.80-99.28%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 7M$ 10M
2025$ 0.00-$ 7M$ 7.55B
2024$ 0.00-$ 14M$ 3M
2023$ 0.00-$ 14M$ 7M
2022$ 0.00-$ 12M$ 9M
IPO2021$ 0.00-$ 12M$ 12M
ACXP - Acurx Pharmaceuticals LLC logo

Acurx Pharmaceuticals LLC fundamental performance

Across Acurx Pharmaceuticals LLC's full reported history, from 2021 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 12M to -$ 7M. Revenue increased in 0% of the years measured; net income in 80%.

Membership

Explore ACXP with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies